The Paediatric Adaptive Sepsis Platform Trial (PASSPORT) is a different type of study called an adaptive platform trial (APT). The platform allows researchers assess multiple treatments at the same time. The adaptations allow researchers to improve the treatments under investigation over time. 
PASSPORT will be conducted in multiple centres across Australia and New Zealand and scaled to include other  countries globally.

This adaptive platform trial  will help us find effective treatments quicker and improve global outcomes for critically ill children with sepsis.

The trial will include children aged one month to 18 years with probable sepsis and will start enrolling patients in 2027.

PASSPORT Platform

Org chart

Teams

Offices